Results from the study using liquid biopsy to detect copy number variations (CNVs), especially PTEN copy number loss, are now published in JCO Precision Oncology. Predicine, Inc. today announced results from a prostate cancer liquid biopsy study evaluating the landscape of genomic alterations in 231 patients with metastatic castration-resistant prostate cancer (mCRPC) from US and...
Predicine to Introduce PredicineALERT MRD Assay and Present 12 Posters at AACR 2023 Conference